Related Experiment Videos
Indication for nateglinide in type 2 diabetes mellitus
Hirofumi Kishikawa1, Yosuke Okada, Kazuko Kanda
1First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu 807-8555, Japan.
Journal of UOEH
|July 1, 2005
Summary
Nateglinide effectively manages postprandial hyperglycemia in early type 2 diabetes, particularly benefiting young, obese patients without microangiopathy. This insulin secretagogue offers a physiologically preferable treatment option.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Postprandial hyperglycemia is linked to arteriosclerosis and impaired glucose tolerance.
- Nateglinide is a rapid-acting insulin secretagogue targeting postprandial hyperglycemia.
- Understanding optimal patient profiles for nateglinide is crucial for effective treatment.
Purpose of the Study:
- To identify background factors predicting nateglinide efficacy in type 2 diabetes patients.
- To determine the optimal indications for nateglinide therapy.
- To evaluate nateglinide's effect on insulin secretory dynamics.
Main Methods:
- Retrospective analysis of type 2 diabetic patient background factors.
- Assessment of patient response to nateglinide treatment.
- Evaluation of microangiopathy and prior medication history.
Main Results:
- Nateglinide demonstrated highest efficacy in young and obese patients.
- Fewer responders had microangiopathy or were on prior oral hypoglycemic agents/sulfonylureas.
- The drug improved late hyperinsulinemia and normalized secretory dynamics in an obese patient, irrespective of baseline HbA1c.
Conclusions:
- Nateglinide is a physiologically preferable drug for early type 2 diabetes, especially in patients without microangiopathy.
- Optimal candidates include young, obese individuals with postprandial hyperglycemia.
- Nateglinide effectively improves insulin secretory dynamics, offering a valuable therapeutic option.